Fig 1: Navitoclax treatment ameliorates EAE and reduces senescent microglial phenotypes in middle-aged mice. (A) Clinical course of EAE in middle-aged mice treated with vehicle (black, n = 12) or navitoclax (red, n = 5), starting at symptom onset. Navitoclax (5 mg/kg; HY-10087, MedChemExpress) suspended in a 10% DMSO/30% PEG300/10% Tween80/50%water solution, or vehicle solution alone, was administered i.v. into the tail vein. (A) Clinical score curve for middle-aged mice treated with either vehicle (black, n=12) or navitoclax (red, n=5) beginning at the time of clinical disease onset. Left: daily mean clinical scores; Middle left: area under the clinical score curve (AUC); Middle right: mean peak clinical scores; Right: survival over time. (B) Histograms and corresponding geometric mean fluorescent intensity (gMFI) showing the expression of CD14 (left) and TREM2 (right), gated on CD45int CD11b+ microglia. Data are representative of 2 individual experiments. All experiments were performed with female C57BL/6 mice purchased from Charles River. Statistical significance was determined using unpaired 2-tailed Student’s t test. Curves in the left panel of A were compared using a mixed effects model. Error bars indicate mean ± SEM. *p < 0.05, **p < 0.01.